Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
Uloženo v:
| Název: | Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study |
|---|---|
| Autoři: | Weilun Meng, Haotian Yang, Zhongyuan Ren, Jiawen Wu, Yixing Zheng, Song Zhao, Chong Xu, Rusitanmujiang Maimaitiaili, Jiamin Tang, Shikai Yu, Jing Xiong, Chen Chi, Yawei Xu, Yi Zhang |
| Zdroj: | ESC Heart Fail ESC Heart Failure, Vol 12, Iss 1, Pp 229-238 (2025) |
| Informace o vydavateli: | Wiley, 2024. |
| Rok vydání: | 2024 |
| Témata: | all‐cause death, Male, Heart Failure, Aged, 80 and over, China, community‐dwelling elderly, Stroke Volume, Prognosis, cardiovascular death, Survival Rate, RC666-701, Cause of Death, Diseases of the circulatory (Cardiovascular) system, Humans, Original Article, Female, Independent Living, early‐stage HFpEF, MACEs, Aged, Follow-Up Studies, Retrospective Studies |
| Popis: | ObjectiveHeart failure with preserved ejection fraction (HFpEF) is a growing concern among the elderly population, significantly impacting morbidity and mortality rates. This study aimed to screen and investigate the characteristics and prognosis of early‐stage HFpEF in the elderly.MethodsA total of 1789 community‐dwelling individuals aged over 65 from northern Shanghai were enrolled. According to American Heart Association (AHA) guidelines, participants were classified into four groups: HFpEF stage 0, HFpEF stage A, HFpEF stage B and HFpEF stage C. Major endpoints included major adverse cardiovascular events (MACEs), all‐cause death and cardiovascular death.ResultsAfter a mean follow‐up period of 7.10 ± 1.27 years, 1623 elderly subjects were included [HFpEF stage 0 (10.3%), HFpEF stage A (16.3%), HFpEF stage B (60.6%) and HFpEF stage C (12.8%)]. Patients with HFpEF stage A, HFpEF stage B and HFpEF stage C exhibited more MACEs than those in HFpEF stage 0 (P P P P P P ConclusionsCompared with those with HFpEF stage 0, patients with HFpEF, whether in stage B or C, exhibit significantly higher cardiovascular and all‐cause mortality in the elderly. This study underscores the importance of early‐stage HFpEF screening, particularly in older, asymptomatic stage B individuals. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 2055-5822 |
| DOI: | 10.1002/ehf2.15060 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39267258 https://doaj.org/article/95156917a46242af99df3007bbbd3a01 |
| Rights: | CC BY NC ND URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| Přístupové číslo: | edsair.doi.dedup.....3c8e37b6fe720632989468a79c4e1866 |
| Databáze: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | ObjectiveHeart failure with preserved ejection fraction (HFpEF) is a growing concern among the elderly population, significantly impacting morbidity and mortality rates. This study aimed to screen and investigate the characteristics and prognosis of early‐stage HFpEF in the elderly.MethodsA total of 1789 community‐dwelling individuals aged over 65 from northern Shanghai were enrolled. According to American Heart Association (AHA) guidelines, participants were classified into four groups: HFpEF stage 0, HFpEF stage A, HFpEF stage B and HFpEF stage C. Major endpoints included major adverse cardiovascular events (MACEs), all‐cause death and cardiovascular death.ResultsAfter a mean follow‐up period of 7.10 ± 1.27 years, 1623 elderly subjects were included [HFpEF stage 0 (10.3%), HFpEF stage A (16.3%), HFpEF stage B (60.6%) and HFpEF stage C (12.8%)]. Patients with HFpEF stage A, HFpEF stage B and HFpEF stage C exhibited more MACEs than those in HFpEF stage 0 (P P P P P P ConclusionsCompared with those with HFpEF stage 0, patients with HFpEF, whether in stage B or C, exhibit significantly higher cardiovascular and all‐cause mortality in the elderly. This study underscores the importance of early‐stage HFpEF screening, particularly in older, asymptomatic stage B individuals. |
|---|---|
| ISSN: | 20555822 |
| DOI: | 10.1002/ehf2.15060 |